RET and non-small cell lung carcinoma: RXDX-105 is a VEGF receptor (VEGFR)-sparing RET inhibitor, with a phase Ib study on 21 untreated RET fusion-positive NSCLC sufferers, observed response in 6 of the 8, non-KIF5B-RET fusion positive patients.